Transcat (TRNS) Competitors

98.3% of Transcat shares are held by institutional investors. 2.8% of Transcat shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Transcat presently has a consensus target price of $105.50, suggesting a potential upside of 19.33%. Alamar Biosciences has a consensus target price of $30.00, suggesting a potential upside of 5.56%. Given Transcat's higher possible upside, equities analysts clearly believe Transcat is more favorable than Alamar Biosciences.

In the previous week, Alamar Biosciences had 7 more articles in the media than Transcat. MarketBeat recorded 8 mentions for Alamar Biosciences and 1 mentions for Transcat. Transcat's average media sentiment score of 1.87 beat Alamar Biosciences' score of 0.78 indicating that Transcat is being referred to more favorably in the media.

Transcat has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Transcat has a net margin of 1.62% compared to Alamar Biosciences' net margin of 0.00%. Transcat's return on equity of 5.84% beat Alamar Biosciences' return on equity.

In the previous week, Transcat and Transcat both had 1 articles in the media. Transcat's average media sentiment score of 1.87 equaled Allient'saverage media sentiment score.

98.3% of Transcat shares are owned by institutional investors. Comparatively, 61.6% of Allient shares are owned by institutional investors. 2.8% of Transcat shares are owned by company insiders. Comparatively, 15.0% of Allient shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Allient has higher revenue and earnings than Transcat. Allient is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Transcat has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Allient has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market.

Transcat presently has a consensus price target of $105.50, suggesting a potential upside of 19.33%. Allient has a consensus price target of $77.33, suggesting a potential downside of 14.54%. Given Transcat's higher probable upside, equities analysts plainly believe Transcat is more favorable than Allient.

Allient has a net margin of 4.25% compared to Transcat's net margin of 1.62%. Allient's return on equity of 12.47% beat Transcat's return on equity.

Eyepoint Pharmaceuticals has a beta of 1.73, meaning that its stock price is 73% more volatile than the broader market. Comparatively, Transcat has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

Transcat has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

In the previous week, Eyepoint Pharmaceuticals had 3 more articles in the media than Transcat. MarketBeat recorded 4 mentions for Eyepoint Pharmaceuticals and 1 mentions for Transcat. Transcat's average media sentiment score of 1.87 beat Eyepoint Pharmaceuticals' score of 0.88 indicating that Transcat is being referred to more favorably in the news media.

Eyepoint Pharmaceuticals currently has a consensus target price of $44.29, suggesting a potential upside of 200.85%. Transcat has a consensus target price of $105.50, suggesting a potential upside of 19.33%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Transcat.

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.3% of Transcat shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Comparatively, 2.8% of Transcat shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Transcat has a net margin of 1.62% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Transcat's return on equity of 5.84% beat Eyepoint Pharmaceuticals' return on equity.

Frequency Electronics currently has a consensus price target of $43.67, suggesting a potential downside of 23.83%. Transcat has a consensus price target of $105.50, suggesting a potential upside of 19.33%. Given Transcat's higher possible upside, analysts plainly believe Transcat is more favorable than Frequency Electronics.

Frequency Electronics has a net margin of 10.78% compared to Transcat's net margin of 1.62%. Frequency Electronics' return on equity of 12.69% beat Transcat's return on equity.

In the previous week, Frequency Electronics had 4 more articles in the media than Transcat. MarketBeat recorded 5 mentions for Frequency Electronics and 1 mentions for Transcat. Transcat's average media sentiment score of 1.87 beat Frequency Electronics' score of 0.31 indicating that Transcat is being referred to more favorably in the news media.

Frequency Electronics has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market. Comparatively, Transcat has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Frequency Electronics has higher earnings, but lower revenue than Transcat. Frequency Electronics is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

58.6% of Frequency Electronics shares are held by institutional investors. Comparatively, 98.3% of Transcat shares are held by institutional investors. 28.0% of Frequency Electronics shares are held by insiders. Comparatively, 2.8% of Transcat shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.